Navigation Links
Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
Date:11/3/2011

THE WOODLANDS, Texas, Nov. 3, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. David Powell, senior vice president of metabolism research, will present data from clinical and preclinical studies of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), at the Cambridge Healthtech Institute's Diabetes Drug Discovery conference in Boston, Massachusetts on Friday, November 4, 2011.

In clinical studies to date, LX4211 has demonstrated a favorable safety profile and beneficial effects on multiple parameters of glycemic control and cardiovascular health.  Recent studies in healthy subjects have shown that LX4211 substantially decreases postprandial glucose levels without hypoglycemia and substantially reduces triglycerides, results that have not been reported for SGLT2-selective inhibitors.  Data from a mechanistic study in patients with type 2 diabetes demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  In addition, postprandial release of GLP-1 and PYY from the gastrointestinal (GI) tract has been observed in preclinical studies of SGLT1 knockout mice but not in SGLT2 knockout mice, indicating that inhibition of SGLT1 function may trigger the postprandial release of these important regulators of glycemic and appetite control.

For more information on this program or to download a copy of the presentation, please visit www.lexpharma.com.

About Lexicon
Lexicon is a biopharmaceutical company focused on disco
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research and ... Hypodermic Needles Market 2014-2018" report to their offering. ... A hypodermic needle is a hollow needle commonly used ... or or to extract fluids from it. A hypodermic ... to inject substances that cannot be ingested. Hypodermic needles ...
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... -- Neurelis, Inc. ("Neurelis") today announced an agreement with ... by Biotie to purchase Neurelis, clearing the way for ... for pediatric and adult epilepsy patients who experience acute ... has advanced the development program for NRL-1 and worked ... required for NDA submission to the FDA.  Given the ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
(Date:7/14/2014)... 14, 2014 Sometimes, thinking “inside the ... Playground announces its first product release, Joyboxx™ - The ... system. , Inventor and CEO, Deborah Semer ... have a storage solution for their ‘toys’ after she ... adult retail industry. , Semer met 30-year industry veteran ...
(Date:7/14/2014)... July 14, 2014 The Cabin Chiang ... its new Alumni Community website – a ... to help them maintain lifelong recovery wherever they live ... providing clients the tools to help them maintain their ... essential part of any reputable treatment programme. As a ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... The FDA informed on July 11, that one lot ... mL, Flexible Container, by Hospira Inc., is recalled due ... parenteral replacement of extracellular losses of fluid and electrolytes, ...
(Date:7/14/2014)... According to the Blood Pressure Solution book review recently updated ... series of new information on high blood pressure . ... help readers understand more about blood pressure. The book shows ... to control hypertension naturally. , Blood Pressure ... by Ken Burge, a medical researcher and health consultant. Since ...
(Date:7/14/2014)... to the Boost Your Bust book review recently updated by Vkool.com, ... how to increase the size of their breasts naturally without medication ... , Chapter 1 – What Are Your Breasts And ... Natural Breast Enlargement Works , Chapter 3 – The ... 4 – The Groundwork , Chapter 5 – Personal ...
Breaking Medicine News(10 mins):Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3
... research published in The Lancet states that, consuming a ... faster information processing and memory in the older adults. ... reduced levels of folate, and elevated levels of amino ... restricts cognitive ability, increasing the risk of dementia. ...
... the NHS trust to cater to mental problems afflicting the ... a document enabled by Durham County Council's inquiry committee, recognized ... in Durham and Darlington. The report threw light on the ... problems across six primary care trust areas in the region. ...
... the sake of good health., Students of Pittsburgh’s Plum ... last 10 months; via cafeteria meals. This was announced Thursday. ... by-products such as hulls of oats, soybeans, peas and rice, ... school meals to cut down calories while preserving a favorable ...
... showed reasonable resistance to Tamiflu, an antiviral, in two Egyptians who ... the medical community. ,The report also states that the ... in 2005. The occurrence of this strain in Egypt reveals that ... Tamiflu by the birdflu virus has not changed the WHO stance ...
... for short-term relief of chronic back pain, but their ... by researchers at Yale School of Medicine, who also ... in 24 percent of cases. ,“Patients with ... medications are used despite the concerns clinicians have with ...
... molecule that is part of a complex signaling network ... periventricular heterotopia (PVH), a congenital brain malformation, Yale School ... often leads to a variety of neurological disorders such ... It has many environmental and genetic causes, but is ...
Cached Medicine News:Health News:Long-Term Narcotics Use for Back Pain May Be Ineffective and Lead to Abuse 2Health News:Missing Molecule Has Important Role in a Developmental Brain Abnormality 2
M2 cemented hip stem....
Porous foundation 480 series....
Cemented foundation 460 series....
Porous foundation 440 series....
Medicine Products: